Replies to post #810242 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

You are arguing to a wall . ILT/Slave/Ds etc copy and paste AI chat outputs . I don't think they even read the long drivels , let alone fact check the veracity . LSE is open already and you will see excuses from them about why it didn't happen today .

[ilovetech]

Structural Reality vs. The 48-Hour "Binary Trap"
The current noise attempting to "ringfence" Monday and Tuesday as a "failure" for Northwest Biotherapeutics is a classic case of misinterpreting structural milestones as daily press releases. Here is the professional reality versus the iHub narrative:
1. The POATR Activation: Today Is a Gateway, Not a Goalpost
Today, January 19, 2026, the UK officially implemented the Public Offers and Admissions to Trading Regulations (POATR) and the new PRM Sourcebook.
The High Ground: This is a systemic change that streamlines capital raising and secondary issuances for companies already in the UK ecosystem.
The Reality: Today isn't a "date for an NWBO surprise"—it's the date the playground equipment changed for everyone. NWBO’s multi-year effort—acquiring Advent BioServices, building out Sawston, and cleaning up its share structure—was precisely about being positioned for this new, modern UK regulatory environment.
2. The 75% Rule: Dismantling the "Delayed Friction" Myth
Skeptics are banking on the idea that NWBO faces a months-long "prospectus approval" delay. They are citing a law that was repealed at 7:00 AM London time today.
PRM 1.4.3R: Under the new rules, the threshold for requiring a prospectus for further issuances has been raised from 20% to 75%.
The Exemption: Because NWBO already has an instrument admitted to the LSE (0K95), they can utilize this exemption for secondary admissions of nearly 2 billion shares without the "FCA-approved prospectus" friction. The "wall" the shorts are praying for was effectively torn down today.
3. The "IPO Fallacy" and "Junior Varsity" Noise
The claim that NWBO "doesn't meet requirements" is a category error. Skeptics often cite Main Market rules (3-year revenue history) to imply a company is "blocked."
The Professional Pathway: High-growth biotechs use the AIM (Alternative Investment Market), which has no such revenue requirements.
Big League Readiness: You don't buy a UK manufacturing subsidiary (Advent) and build out a Grade C suite in Sawston to play on the "JV" team. Those are moves for a company preparing for a high-tier entry under the new, streamlined listing rules.
Bottom Line:
Success is not measured by a headline in the first five hours of a new regulatory regime. It is measured by the commercial activation of a therapy. While some are busy watching the clock for a "Monday surprise," the company is executing on a billion-dollar infrastructure shift. If you're betting on a "prospectus delay" in 2026, you're reading a 2025 rulebook.